Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

$MESO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $MESO alert in real time by email
SC 13G/A 1 mesoblast-sc13ga_100924.htm AMENDMENT TO FORM SC 13G

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Mesoblast Limited

(Name of Issuer)

 

Ordinary Shares

(Title of Class of Securities)

 

590717104

(CUSIP Number)

 

See Item 2(b) below

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

9 October 2024

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

 

   

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No. 590717104   13G   Page 2 of 10 Pages

 

1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Gregory George

 

   
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

   
3.  

SEC USE ONLY

 

   
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Bahamas

 

   

         

NUMBER OF SHARES BENEFICIALLY OWNED BY

EACH

REPORTING

PERSON WITH

5.

SOLE VOTING POWER

 

115,041,947

6.

SHARED VOTING POWER

 

83,103,240

7.

SOLE DISPOSITIVE POWER

 

115,041,947

8.

SHARED DISPOSITIVE POWER

 

83,103,240

         

9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 198,145,187

   
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

   
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

17.35%

   
12.  

TYPE OF REPORTING PERSON (see instructions)

 IN

   

 

 

 

 

 

CUSIP No. 590717104   13G   Page 3 of 10 Pages

  

1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

James George

 

   
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

   
3.  

SEC USE ONLY

 

   
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States of America

 

   

         

NUMBER OF SHARES BENEFICIALLY OWNED BY

EACH

REPORTING

PERSON WITH

5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

6,000,000

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

6,000,000

         

9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 6,000,000

   
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

   
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.53%

   
12.  

TYPE OF REPORTING PERSON (see instructions)

 IN

   

 

 

 

 

CUSIP No. 590717104   13G   Page 4 of 10 Pages

 

1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Grant George

 

   
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

   
3.  

SEC USE ONLY

 

   
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States of America

 

   

         

NUMBER OF SHARES BENEFICIALLY OWNED BY

EACH

REPORTING

PERSON WITH

5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

6,000,000

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

6,000,000

         

9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

6,000,000

   
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

   
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.53%

   
12.  

TYPE OF REPORTING PERSON (see instructions)

 IN

   

  

 

 

 

CUSIP No. 590717104   13G   Page 5 of 10 Pages

  

1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

G to the Fourth Investments, LLC

 

   
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

   
3.  

SEC USE ONLY

 

   
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Nevada

 

   

         

NUMBER OF SHARES BENEFICIALLY OWNED BY

EACH

REPORTING

PERSON WITH

5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

71,103,240

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

71,103,240

         

9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

71,103,240

   
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

   
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

6.23%

   
12.  

TYPE OF REPORTING PERSON (see instructions)

 OO

   

  

 

 

 

CUSIP No. 590717104   13G   Page 6 of 10 Pages

 

Item 1.

  (a)

Name of Issuer

    Mesoblast Limited
     
  (b)

Address of Issuer’s Principal Executive Offices

    Level 38, 55 Collins Street, Melbourne 3000, Australia

 

Item 2.

  (a)

Name of Person Filing

   

Gregory George, James George, Grant George and G to the Fourth Investments, LLC (the “Reporting Persons”)

     
  (b)

Address of the Principal Office or, if none, residence:

   

The principal business office of the Reporting Persons is:

 

Gregory George

371 Channelside Walkway

PH 1702, Tampa

Florida, 33602

 

G to the Fourth Investments, LLC

831 Laca Street

Dayton

Nevada, 89403

 

James George

371 Channelside Walkway

PH 1702, Tampa

Florida, 33602

 

Grant George

371 Channelside Walkway

PH 1702, Tampa

Florida, 33602

 

  (c)

Citizenship

   

Gregory George is a citizen of the Bahamas.

 

James George and Grant George are U.S. citizens.

 

G to the Fourth Investments, LLC, is organized in Nevada.

     
  (d)

Title of Class of Securities

   

Ordinary Shares / American Depositary Receipts

     
  (e)

CUSIP Number

    590717104

 

 

 

CUSIP No. 590717104   13G   Page 7 of 10 Pages

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not Applicable  

 

Item 4.  Ownership.

The ownership information below represents beneficial ownership of ordinary shares as represented by American Depositary Receipts by the Reporting Persons as of July 10, 2024, based upon 1,141,784,114 ordinary shares of the issuer outstanding as of October 9, 2024.

 

Gregory George is the sole beneficial owner of 115,041,947 ordinary shares, which include 6,830,602 ordinary shares underlying warrants and 9,200,625 ordinary shares held in the form of American Depositary Receipts (“ADRs”).

 

Gregory George is a manager of G to the Fourth Investments, LLC and has discretionary authority to vote and dispose of 71,103,240 ordinary shares held by G to the Fourth Investments, LLC. Gregory George may be deemed to be the beneficial owner of these shares.

 

Gregory George has discretionary authority to vote and dispose of 6,000,000 ordinary shares held in the form of ADRs by his son James George. Gregory George may be deemed to be the beneficial owner of these shares.

 

Gregory George has discretionary authority to vote and dispose of 6,000,000 ordinary shares held in the form of ADRs by his son Grant George. Gregory George may be deemed to be the beneficial owner of these shares.

 

Gregory George

 

  a) Amount beneficially owned:  198,145,187

 

  b) Percent of class:  17.35%

 

  c) Number of shares as to which the person has:

 

  i. Sole power to vote or to direct the vote: 115,041,947

 

  ii. Shared power to vote or to direct the vote: 83,103,240

 

  iii. Sole power to dispose or to direct the disposition of: 115,041,947

 

  iv. Shared power to dispose or to direct the disposition of: 83,103,240

 

James George

 

  a) Amount beneficially owned:  6,000,000

 

  b) Percent of class:  0.53%

 

  c) Number of shares as to which the person has:

 

  i. Sole power to vote or to direct the vote: 0

 

  ii. Shared power to vote or to direct the vote: 6,000,000

 

  iii. Sole power to dispose or to direct the disposition of: 0

 

  iv. Shared power to dispose or to direct the disposition of: 6,000,000

 

 

 

 

CUSIP No. 590717104   13G   Page 8 of 10 Pages

 

Grant George

 

  a) Amount beneficially owned:  6,000,000

 

  b) Percent of class:  0.53%

 

  c) Number of shares as to which the person has:

 

  i. Sole power to vote or to direct the vote: 0

 

  ii. Shared power to vote or to direct the vote: 6,000,000

 

  iii. Sole power to dispose or to direct the disposition of: 0

 

  iv. Shared power to dispose or to direct the disposition of: 6,000,000

 

G to the Fourth Investments, LLC

 

  a) Amount beneficially owned:  71,103,240

 

  b) Percent of class:   6.23%

 

  c) Number of shares as to which the person has:

 

  i. Sole power to vote or to direct the vote: 0

 

  ii. Shared power to vote or to direct the vote: 71,103,240

 

  iii. Sole power to dispose or to direct the disposition of: 0

 

  iv. Shared power to dispose or to direct the disposition of: 71,103,240

 

Item 5.  Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not Applicable.

Item 8.  Identification and Classification of Members of the Group.

Not Applicable.

 

 

CUSIP No. 590717104   13G   Page 9 of 10 Pages

Item 9.  Notice of Dissolution of Group.

Not Applicable.

Item 10.  Certification.

       
  (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
         
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
         
  (b)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  

 

 

 

CUSIP No. 590717104   13G   Page 10 of 10 Pages

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

/s/ Gregory George

Signature

   
 

Gregory George

Name

  /s/ James George
  Signature
   
 

James George

Name

 

  /s/ Grant George
  Signature
   
 

Grant George

Name

 

 

/s/ Gregory George

Signature

   
 

G to the Fourth Investments, LLC

   
  Gregory George
  Name
   
 

Manager

 

Title

 

 

Get the next $MESO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MESO

DatePrice TargetRatingAnalyst
12/23/2024Buy → Hold
Jefferies
9/24/2024$12.00Hold → Buy
Maxim Group
8/29/2024Hold → Buy
Jefferies
7/23/2024$4.00 → $11.00Neutral → Overweight
Piper Sandler
8/31/2023Hold → Buy
Jefferies
8/7/2023Buy → Hold
Maxim Group
8/4/2023$7.00 → $2.00Overweight → Neutral
Piper Sandler
8/4/2023Outperform → Mkt Perform
William Blair
More analyst ratings

$MESO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

    NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation. Mesoblast filed a request for a Type B meeting during the last quarter, in line with previous guidance, and expects to have the meeting during this quarter. The meeting will be held under Mesoblast's Regenerative Medicines Advanced Therap

    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • First Three Children to Commence Treatment With Ryoncil®

    NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services, for Ryoncil® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication. The NDRA agreement with Mesoblast means that the U.S. Government now provides inpatient and outpatient access for a treatment course of Ryoncil® to the approximately 40% of U.S. children covered by

    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Ryoncil® is Now Available for Purchase in the United States

    NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, is now available for purchase in the United States. Ryoncil® is approved for treatment of pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), a condition with high mortality rates. The recommended dosage of Ryoncil® for treatment of pediatric SR-aGvHD is 2×106 MSC/kg body w

    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$MESO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MESO
SEC Filings

See more

$MESO
Leadership Updates

Live Leadership Updates

See more
  • Dr. Gregory George MD PhD Joins Mesoblast Board

    NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast's largest shareholder, to its Board of Directors. Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization. Mesoblast Founder and Chief

    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

    $AVTX
    $DRRX
    $HALO
    $MESO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medicinal Chemicals and Botanical Products
  • Coya Therapeutics ("Coya") Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner

    Dr. Grossman brings over 20 years of drug development expertise having held senior executive leadership positions in large and small pharmaceutical companies leading the development and FDA approval of numerous multi-billion dollar blockbuster drugs addressing significant unmet medical needs particularly across CNS disorders. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE: 532296) as well as Chief Medical Officer at Mesoblast, Inc. (NASDAQ:MESO). Dr. Grossman is Board-Certified in Psychiatry and a Fellow of the American Psychiatric Association

    $COYA
    $MESO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$MESO
Financials

Live finance-specific insights

See more
  • Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

    NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024. Mesoblast Chief Executive Silviu Itescu said: "During the past year we have built significant momentum in our interactions with the United States Food and Drug Administration (FDA) across each of our Phase 3 products. I am very pleased that our Biologics License Application (BLA) resubmission for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD)

    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

    NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: "We were very busy operationally during the last quarter and continued to have positive engagement with the United States Food and Drug Administration (FDA) across our lead programs. We have strengthened our balance sheet while maintaining overall spending constraint in line with our corporate objectives. For our product Ryoncil® (remestemcel-L) for life-threatening steroid-ref

    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

    NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones. Mesoblast Chief Executive Silviu Itescu said: "We had anticipated that remestemcel-L would have been approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), a condition with a high mortality where there are no approved therapies for children under 12 years old. During the six-month B

    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$MESO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more